HB1156 – Pharmacists – Therapy Management Contract – Form

Supplemental Document

This type of care coordination is performed under a specific state regulation, that is, Md. Code Regs. 10.34.29.06.

Have coverage limitation(s) in place for medication(s) with a high risk for dependence and/or abuse, or

Meet the following criteria:

You have three or more of these conditions:

Asthma

Chronic Heart Failure (CHF)

Chronic Obstructive Pulmonary Disease (COPD)

Diabetes

Dyslipidemia

Hypertension

Chronic alcohol & drug dependence

HIV/AIDS

You take eight or more maintenance medications covered by your plan

You are likely to spend more than \$4,935 in prescription drug costs in 2023

A. A therapy management contract shall be signed by the:

- (1) Authorized prescriber or authorized prescribers involved in the management of the patient under a prescriber-pharmacist agreement;
- (2) Pharmacist or pharmacists involved in the management of the patient under a prescriber-pharmacist agreement; and

- (3) Patient receiving care under the therapy management contract.
- B. A therapy management contract shall contain:
 - (1) A list of allowable substitutions of chemically dissimilar drugs, if any;
 - (2) A statement that:
 - (a) None of the parties involved in the therapy management contract have been:
 - (i) Coerced into participating in the therapy management contract;
 - (ii) Given economic incentives, excluding normal reimbursement for services

rendered; or

- (iii) Involuntarily required to participate in the therapy management contract; and
- (b) The pharmacist shall notify the authorized prescriber under the terms of the prescriber-pharmacist agreement if the pharmacist:
 - (i) Modifies the dose or agent under the therapy management contract; or
 - (ii) Detects an abnormal result from an assessment activity;
- (3) Notice to the patient stating:
 - (a) That the patient may terminate the therapy management contract at any time; and
 - (b) The procedure by which the patient may terminate the therapy management contract;
- (4) A procedure for periodic review by the authorized prescriber of the drugs modified under the prescriber-pharmacist agreement or changed with the consent of the authorized prescriber,

- (5) A reference to the protocol or protocols under which the pharmacist shall act; and
- (6) Exceptions or limitations to the protocol or protocols for the specific patient.